Form 4: Caribou Biosciences CEO Rachel Haurwitz Reports Stock and Option Awards
SEC Form 4 Filing
Rachel Haurwitz, CEO of Caribou Biosciences, reports the acquisition of restricted stock units and stock options.
Summary
- Rachel E. Haurwitz, President and CEO of Caribou Biosciences, reported changes in beneficial ownership of the company's stock on February 21, 2025.
- On February 20, 2025, Haurwitz acquired 136,750 shares of common stock in the form of restricted stock units (RSUs).
- These RSUs vest in four equal annual installments starting February 20, 2026, contingent upon continued service to the Issuer.
- Haurwitz also acquired options to purchase 618,250 shares of common stock at an exercise price of $1.41, expiring on February 19, 2035.
- 25% of these options vest on February 20, 2026, with the remaining vesting monthly over the following 36 months, also subject to continued service.
- Following these transactions, Haurwitz directly owns 295,450 shares of common stock and indirectly owns 3,349,395 shares through The City Canyon Family Trust.
- She also directly owns options to purchase 618,250 shares of common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The document reflects standard executive compensation practices, which are generally viewed favorably as they align management's interests with shareholders. There are no red flags or negative indicators.
Positives
- The grant of RSUs and stock options to the CEO aligns her interests with those of the shareholders, incentivizing her to drive long-term value creation.
- The vesting schedules for both the RSUs and options encourage continued service and commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.
Industry Context
Stock and option awards are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. The vesting schedules are designed to retain key personnel and reward long-term performance.
Comparison to Industry Standards
- Stock option grants and RSU awards are standard compensation practices in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
- Vesting schedules, typically spanning three to four years, are designed to incentivize long-term commitment and performance.
- Comparable companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- Shareholders: The equity grants align the CEO's interests with shareholder value creation.
- Employees: The grants may have a positive impact on employee morale as they demonstrate the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| May 31, 2021 | Date of The City Canyon Family Trust |
| February 20, 2025 | Date of transaction: Acquisition of RSUs and stock options |
| February 21, 2025 | Date of Form 4 filing |
| February 20, 2026 | First vesting date for RSUs and initial vesting date for stock options |
| February 19, 2035 | Expiration date for stock options |
Keywords
Caribou Biosciences, Rachel Haurwitz, stock options, RSUs, beneficial ownership, Form 4, CRBU
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.